Generate a tailored SOP for Dr. David Segal. Improve your application with a focused, well-structured draft.
David Segal is a professor at the University of California, Davis, where he specializes in Biochemistry and Molecular Medicine. His research focuses on genome engineering technologies such as Zinc fingers, TALEs, and CRISPR/Cas systems, primarily aimed at targeted gene regulation and therapeutic applications in neurologic disorders. His work examines the molecular therapy for genetic diseases and the potential of programmable DNA-RNA binding platforms to induce long-term changes in the expression of disease-related genes. Segal leads a flagship project on Angelman syndrome, developing therapeutic strategies to reactivate silenced genes in the brain. He collaborates with research groups globally to mitigate risks associated with genetic therapies for related disorders. Besides, he explores epigenetics related to non-genetic mental illnesses, understanding how early life experiences can cause lasting epigenetic changes that affect mental health throughout a person's life. His involvement with the NIH Somatic Cell Genome Engineering consortium aims at advancing methodologies for gene editing in clinical settings, focusing on the development of new viral vectors and detailed assessments of on-target and off-target gene editing in live animal models. Segal has co-authored numerous publications in leading scientific journals, contributing significantly to the fields of molecular genetics and therapeutic interventions for neurological conditions.
Department of Computer Science. GRE is NOT required.